Suzhou Ark Biopharmaceutical Co. Ltd. has synthesized 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).

Lynk Pharmaceuticals Co. Ltd. has disclosed nitrogen-containing heterocyclic compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Shanghai Euregen Biopharma Co. Ltd. has described pyridazine compounds acting as son of sevenless homolog 1 (SOS1)/GTPase KRAS (G12C mutant) interaction inhibitors reported to be useful for the treatment of cancer.

Harvard College has divulged nicotinamide N-methyltransferase (NNMT) inhibitors reported to be useful for the treatment of cancer.

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has identified immunostimulatory antibody-drug conjugates (ISAC) comprising immunomodulators (Toll-like receptor 7 [TLR7] and/or TLR8 agonists) bound to antibodies through cleavable or uncleavable linkers reported to be useful for the treatment of cancer.

Shanghai Curegene Pharmaceutical Co. Ltd. has synthesized macrocyclic compounds acting as 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).

Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceuticals Co. Ltd. have disclosed antibody-drug conjugates (ADC) comprising human monoclonal antibodies targeting ROR1 covalently linked to exatecan through a linker. They are reported to be useful for the treatment of cancer.

Medific Inc. has described substituted thiazolidinedione derivatives acting as sterol regulatory element binding protein (SREBP; SREBF1) inhibitors reported to be useful for the treatment of cancer, particularly brain cancer.

Shanghai Allist Pharmaceuticals Co. Ltd. has divulged EGFR (HER1; erbB1) (mutant) inhibitors reported to be useful for the treatment of cancer.

Suzhou Kintor Pharmaceuticals Inc. has identified proteolysis targeting chimera (PROTAC) compounds comprising cereblon (CRBN) binding moiety covalently linked to Myc proto-oncogene protein (c-Myc), eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1), zinc finger protein helios (IKZF2) and casein kinase 1 isoform α (CK1α).